Bristol-Myers Squibb Issues Voluntary Nationwide Recall of COUMADIN® (warfarin sodium) FOR INJECTION Due to Presence of Particulate Matter | BMS Newsroom

(NEW YORK – June 30, 2014)  – Bristol-Myers Squibb Company (NYSE:BMY) is voluntarily recalling six lots of COUMADIN® FOR INJECTION, 5 mg single-use vials in the U.S. This recall is a precautionary measure based on the company’s investigation of visible particulate matter found in a small number of COUMADIN FOR INJECTION unreleased samples. Bristol-Myers Squibb believes the safety risk to patients is low, and is further mitigated by the product’s prescribing information advising that intravenous drug products be inspected visually prior to administration. 



Bristol-Myers Squibb Issues Voluntary Nationwide Recall of COUMADIN® (warfarin sodium) FOR INJECTION Due to Presence of Particulate Matter | BMS Newsroom